Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

CB2R agonists in the clinics for treating inflammatory diseases

Therapeutic targeting of the tumor microenvironments with cannabinoids and their analogs: Update on clinical trials - ScienceDirect

Full article: At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk

Modulation of pulmonary immune function by inhaled cannabis products and consequences for lung disease, Respiratory Research

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications

Full article: At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk

International Association for the Study of Pain presidential task force on cannabis and cannabinoid analgesia position statement – Recent Publications

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

The endocannabinoid system and its therapeutic exploitation